Of the thousands of compounds active against a target, how many typically pass preclinical testing?

Question

BlackTom AI · Accepted Answer

Question restatement: The prompt asks, among thousands of compounds active against a target, how many typically pass preclinical testing?

Option a. 10–50: This range is higher than commonly cited preclinical pass rates, which are a small fraction of the initial pool. It overstates the progression from discovery to preclinical success.

Option b. 1–5: This range aligns with typical screening-to-preclinical success stories in drug discovery, where only a handful of compounds out of thousands advance due to factors like efficacy, selectivity, toxicity, and pharmacokinetics. It reflects the very selective bottleneck at preclinical advancement.

Option c. 5–10: While closer to reality than some ranges, this still represents a larger fraction than is commonly observed; the attrition rate is very steep, and 5–10 out of thousands would be unusually optimistic given typical discovery pipeline challenges.

Option d. 50-100: This option vastly overestimates the number that survive preclinical testing from a large initial pool; advancing 50–100 compounds would imply a much higher success rate through preclinical screening than is generally observed, given safety, efficacy, and ADME/Tox hurdles.

Why the correct option is correct (b): In early drug discovery, many compounds are identified, but only a tiny subset demonstrates the required potency, selectivity, safety, and drug-like properties to proceed to preclinical studies. The typical attrition rate at this stage is high, often yielding only about a dozen or fewer candidates per thousands initially identified, with 1–5 being a common, cautious estimate of those that advance.

Why the other options are incorrect (a, c, d):
- a incorrect because it overestimates the number that pass to preclinical testing, not accounting for stringent safety and efficacy filters.
- c incorrect since it still overestimates progression likelihood relative to the steep drop-off seen in preclinical qualification.
- d incorrect because it grossly overstates the viable pool remaining after initial screening, contradicting common industry experience of tight selection for preclinical progression.

In summary, option b reflects the widely acknowledged reality that only a small handful of compounds out of thousands advance past preclinical testing due to rigorous requirements across efficacy, safety, and pharmacokinetic criteria.

Of the thousands of compounds active against a target, how many typically pass preclinical testing?单项选择题

类似问题

Which one of the following statements about modern day drug discovery is INCORRECT?

Which one of the following statements regarding early drug discovery approaches is correct?

What was the goal of Pfizer chemists when they developed the drug UK-92.480?

Report the skewness statistic of the journey elapsed time amongst respondents who do not live in regional areas. Report your answer to 2 decimal places.

Report the standard deviation of the journey elapsed time amongst respondents who live in regional areas. Report your answer to one decimal place.

What is the probability that a randomly selected student travelling on Thursday has a travel time greater than 50 minutes? Provide your answer in decimal, and report it to 4 decimal places. Do not report as a percentage.

What is the probability that a randomly selected student travelling on Wednesday has a travel time greater than 50 minutes? Provide your answer in decimal and report it to 4 decimal places. Do not answer as a percentage.

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单